Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
暂无分享,去创建一个
[1] T. Owen-Hughes,et al. Mechanisms for ATP-dependent chromatin remodelling. , 2001, Biochemical Society transactions.
[2] R. Yarden,et al. BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] Manfred Jung,et al. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. , 2002, Journal of medicinal chemistry.
[4] E. Verdin,et al. BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.
[5] S. Grossman,et al. p300/CBP/p53 interaction and regulation of the p53 response. , 2001, European journal of biochemistry.
[6] T. Ekström,et al. The human histone deacetylase family. , 2001, Experimental cell research.
[7] Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. , 2000 .
[8] R. Bürli,et al. Sequence-specific DNA recognition by polyamides. , 1999, Current opinion in chemical biology.
[9] D. Green. Apoptotic Pathways Paper Wraps Stone Blunts Scissors , 2000, Cell.
[10] D. Reinberg,et al. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.
[11] F. Ece,et al. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. , 2001, American journal of respiratory cell and molecular biology.
[12] P. Pandolfi,et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.
[13] K. Blanchard,et al. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. , 1998, Blood.
[14] S. Baylin,et al. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.
[15] H. Saito,et al. deacetylase inhibitors in acute myeloid leukemia cells Up-regulation of costimulatory / adhesion molecules by histone , 2000 .
[16] D. Fairlie,et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. , 2000, Molecular biology of the cell.
[17] D. Bernhard,et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] G. Otterson,et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. , 2001, Cancer research.
[19] J. Licht,et al. Translocations of the RARα gene in acute promyelocytic leukemia , 2001, Oncogene.
[20] P. Pandolfi. Transcription therapy for cancer , 2001, Oncogene.
[21] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[22] Sandy D. Westerheide,et al. The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression , 2001, Molecular and Cellular Biology.
[23] V. Kiermer,et al. The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[24] V. L. Greenberg,et al. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. , 2001, Thyroid : official journal of the American Thyroid Association.
[25] S. Pavey,et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. , 2001, Molecular pharmacology.
[26] F. Marincola,et al. Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1 , 2001, Journal of immunotherapy.
[27] B. Chauffert,et al. Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate , 1998, Cell Death and Differentiation.
[28] W. D. Cress,et al. Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.
[29] S. Kyo,et al. Telomerase activation by histone deacetylase inhibitor in normal cells. , 2001, Nucleic acids research.
[30] L. Pillus,et al. Modifying chromatin and concepts of cancer. , 1999, Current opinion in genetics & development.
[31] Keith D Robertson,et al. DNA methylation, methyltransferases, and cancer , 2001, Oncogene.
[32] D. C. Henckel,et al. Case report. , 1995, Journal.
[33] P. Pandolfi,et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.
[34] F. Behm,et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.
[35] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[36] R. Goodman,et al. CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.
[37] R. Greil,et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts , 2001, Cell Death and Differentiation.
[38] Yang Shi,et al. The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 , 2000, Journal of Virology.
[39] S. Alkan,et al. Histone deacetylase inhibitors induce caspase‐dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17) , 2001, British journal of haematology.
[40] T. Jacks,et al. The retinoblastoma gene family in differentiation and development , 1999, Oncogene.
[41] M. Breuning,et al. Conjunction dysfunction: CBP/p300 in human disease. , 1998, Trends in genetics : TIG.
[42] A. Leutz,et al. Chromatin remodeling in development and differentiation. , 2001, Current opinion in genetics & development.
[43] J. Licht. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML , 2001, Oncogene.
[44] B. Johansson,et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). , 2001, Human molecular genetics.
[45] P G Pelicci,et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.
[46] N. Rosen,et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.
[47] D. Bernhard,et al. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P‐glycoprotein‐expressing cells , 2002, International journal of cancer.
[48] T. Naoe,et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy , 1999, Leukemia.
[49] P. Marks,et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[50] G. Almouzni,et al. The ins and outs of nucleosome assembly. , 2001, Current opinion in genetics & development.
[51] S. Schreiber,et al. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. , 2001, Organic letters.
[52] M. Jung,et al. Inhibitors of histone deacetylase as new anticancer agents. , 2001, Current medicinal chemistry.
[53] Delin Chen,et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.
[54] Peter L. Jones,et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.
[55] W. Gerald,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.
[56] T. Heinzel,et al. Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.
[57] T. Richmond,et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.
[58] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[59] L. Grochow,et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] Eun-Joung Moon,et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.
[61] J. Harbour,et al. Chromatin remodeling and Rb activity. , 2000, Current opinion in cell biology.
[62] Delin Chen,et al. Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.
[63] T. Kouzarides. Histone acetylases and deacetylases in cell proliferation. , 1999, Current opinion in genetics & development.
[64] M. Yoshida,et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[65] J. Mariadason,et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. , 2000, Cancer research.
[66] M. Ptashne,et al. Activation of gene expression by small molecule transcription factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] E. Wintersberger,et al. Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.
[68] C. Allis,et al. Translating the Histone Code , 2001, Science.
[69] S. Grant,et al. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). , 2001, International journal of oncology.
[70] M. Guenther,et al. Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.
[71] J. Herman,et al. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.
[72] R A Rifkind,et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.
[73] Yung-Hyun Choi,et al. Sensing of Ionizing Radiation-induced DNA Damage by ATM through Interaction with Histone Deacetylase* , 1999, The Journal of Biological Chemistry.
[74] T. Tsuruo,et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. , 2001, Cancer research.
[75] M. Okuhara,et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. , 1994, The Journal of antibiotics.
[76] E. Sausville,et al. P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 , 2000, British Journal of Cancer.
[77] Ping Zhu,et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.
[78] T. Tomasi,et al. Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.
[79] I. Kawamura,et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. , 1994, The Journal of antibiotics.
[80] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[81] A. Skoultchi,et al. Coordinating cell proliferation and differentiation. , 2001, Current opinion in genetics & development.
[82] C C Case,et al. Regulation of an Endogenous Locus Using a Panel of Designed Zinc Finger Proteins Targeted to Accessible Chromatin Regions , 2001, The Journal of Biological Chemistry.
[83] R. Marmorstein,et al. Histone acetyltransferases: function, structure, and catalysis. , 2001, Current opinion in genetics & development.
[84] Carlos Caldas,et al. Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.
[85] P. Liberator,et al. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. , 2001, Current medicinal chemistry.
[86] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[87] U. Weidle,et al. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. , 2000, Anticancer research.
[88] Dana M. King,et al. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins , 2001, Cancer Chemotherapy and Pharmacology.
[89] R C Coombes,et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[90] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[91] T. Tamura,et al. In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression , 2001, Oncogene.
[92] J. Herman,et al. DNA methylation, chromatin inheritance, and cancer , 2001, Oncogene.
[93] J. Doly,et al. Inhibition of Histone Deacetylation Induces Constitutive Derepression of the Beta Interferon Promoter and Confers Antiviral Activity , 2001, Journal of Virology.
[94] V. L. Greenberg,et al. Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. , 2001, Thyroid : official journal of the American Thyroid Association.
[95] 深山 正久. p300 Gene Alterations in Colorectal and Gastric Carcinomas , 1997 .
[96] R. Evans,et al. Transcriptional regulation in acute promyelocytic leukemia , 2001, Oncogene.
[97] K. Kandror,et al. Tip60 and HDAC7 Interact with the Endothelin Receptor A and May Be Involved in Downstream Signaling* , 2001, The Journal of Biological Chemistry.
[98] G. Bae,et al. Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells* , 2002, The Journal of Biological Chemistry.
[99] J. Trapani,et al. Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction , 1998, Cell Death and Differentiation.
[100] T. Tsuruo,et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[101] J C Reed,et al. Dysregulation of apoptosis in cancer. , 1998, The cancer journal from Scientific American.
[102] T. Kouzarides,et al. Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription , 2001, The EMBO journal.
[103] R. Weinberg,et al. hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.
[104] L. Grochow,et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[105] Yufang Shi,et al. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression , 1998, Oncogene.
[106] T. Naoe,et al. In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice , 2001, Japanese journal of cancer research : Gann.
[107] K. Naka,et al. Effect of trichostatin A on cell growth and expression of cell cycle‐ and apoptosis‐related molecules in human gastric and oral carcinoma cell lines , 2000, International journal of cancer.
[108] G. Kammer,et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-γ gene and protein expression in lupus T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[109] Paul Tempst,et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex , 1999, Nature Genetics.
[110] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[111] Eric Verdin,et al. Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.
[112] P. Marks,et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.
[113] E. Olson,et al. Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.
[114] 寺尾 泰久. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells , 2002 .
[115] L. Kedes,et al. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. , 2001, Molecular cell.
[116] J. Herman,et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.
[117] L. Guarente,et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.
[118] A. Verdel,et al. Functional significance of histone deacetylase diversity. , 2001, Current opinion in genetics & development.
[119] D. Sterner,et al. Acetylation of Histones and Transcription-Related Factors , 2000, Microbiology and Molecular Biology Reviews.
[120] S. Grant,et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 , 1999, Oncogene.
[121] M. Grunstein,et al. 25 years after the nucleosome model: chromatin modifications. , 2000, Trends in biochemical sciences.
[122] D. Bernhard,et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.